3-Methoxy-nonadecandiol-(1,2) | 94678-25-8

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 3-Methoxy-nonadecandiol-(1,2)
• 英文别名: 3-methoxy-nonadecane-1,2-diol；3-Methoxynonadecane-1,2-diol
• CAS: 94678-25-8
• 化学式: C₂₀H₄₂O₃
• 分子量: 330.552
• InChiKey: XBWFFZHHWCCOFX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.1
• 重原子数：
  23
• 可旋转键数：
  18
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  49.7
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• Detoxification of microbial virulence factors in oral cavity
  申请人：The Procter & Gamble Company

  公开号：US10156566B2

  公开（公告）日：2018-12-18

  A method for identifying constituents for detoxifying oral virulence factors and a method for determining the effectiveness of detoxifying agents.

  一种确定口腔致病因子解毒成分的方法和一种确定解毒剂有效性的方法。
• DETOXIFICATION OF MICROBIAL VIRULENCE FACTORS IN ORAL CAVITY
  申请人：The Procter & Gamble Company

  公开号：EP3292215A1

  公开（公告）日：2018-03-14
• METHODS FOR THE TREATMENT AND AMELIORATION OF ATOPIC DERMATITIS
  申请人：BRAXMEIER Tobias

  公开号：US20110263531A1

  公开（公告）日：2011-10-27

  The present invention relates of the use of certain inner ionic (zwitter ionic) phospholipids, phosphonolipids and phosphate derivatives for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of an immunological disorder related to mast cell sensitization and/or activation. Preferred in this context are Edelfosine, Miltefosine and Perifosine. In a particularly preferred embodiment, the present invention relates to the use of Miltefosine for the preparation of a pharmaceutical composition for the treatment, prevention and/or amelioration of allergic diseases, in particular acute hyperallergic diseases, like asthma, atopic dermatitis and mastocytosis.
• US8394785B2
  申请人：——

  公开号：US8394785B2

  公开（公告）日：2013-03-12
• [EN] METHODS AND COMPOSITIONS FOR TREATING CELL PROLIFERATIVE DISORDERS<br/>[FR] PROCEDE ET COMPOSITIONS POUR TRAITER DES PROLIFERATIONS ANORMALES DE CELLULES
  申请人：——

  公开号：WO1997004761A1

  公开（公告）日：1997-02-13

  [EN] The invention relates to agents and pharmaceutical compositions containing agents that regulate cellular protein kinase activity. Such compositions, when administered to cells expressing activated ras, induce these cells to undergo apoptosis. These compositions and agents can be used to treat diseases associated with protein kinase activity including carcinomas, sarcomas, lymphosarcomas, leukemias and other diseases which correlate with increased protein kinase activity and especially protein kinase C activity. The invention also relates to methods for determining the efficacy of chemotherapeutic agents and to methods for characterizing tumors by screening for reduced protein kinase activity.
  [FR] L'invention concerne des agents et des compositions pharmaceutiques contenant des agents qui régulent l'activité de la protéine kinase cellulaire. Ces compositions, lorsqu'elles sont administrées à des cellules exprimant le gène ras, induisent une apoptose de ces cellules. Ces compositions et ces agents peuvent être utilisés pour traiter des maladies associées à l'activité de la protéine kinase, en particulier les carcinomes, les sarcomes, les lymphosarcomes, les leucémies et d'autres maladies qui s'accompagnent d'une augmentation de l'activité de la protéine kinase et en particulier de la protéine kinase C. L'invention concerne également des procédés pour déterminer l'efficacité d'agents chimiothérapeutiques et des procédés pour caractériser des tumeurs, par la détermination de la diminution de l'activité protéine kinase.